Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma.
Positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) has been successfully evaluated in the management of non-Hodgkin's lymphoma (NHL).1-3 Histological transformation (HT) of indolent lymphoma is a dramatic event that occurs in 5-10% of the patients and carries a dismal prognosis.4,5 Previous studies prove that indolent lymphoma entities show a lower FDG uptake when compared with aggressive lymphomas.6-8 We therefore postulated that FDG-PET/CT identifies aggressive transformation sites and can guide biopsies.
Bodet-Milin
Caroline
C
Kraeber-Bodéré
Françoise
F
Moreau
Philippe
P
Campion
Loïc
L
Dupas
Benoît
B
Le Gouill
Steven
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D001706:Biopsy / Q000379:methods*; D018450:Disease Progression; D005260:Female; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D015642:Radiology, Interventional / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014057:Tomography, X-Ray Computed / Q000379:methods*
D014408:Biomarkers, Tumor; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18